American Journal of Kidney Diseases
Volume 55, Issue 3 , Pages 463-473 , March 2010

A Health Policy Model of CKD: 2. The Cost-Effectiveness of Microalbuminuria Screening

  • Thomas J. Hoerger, PhD

      Affiliations

    • RTI International, Research Triangle Park, NC
    • Corresponding Author InformationAddress correspondence to Thomas J. Hoerger, PhD, RTI International, 3040 Cornwallis Rd, PO Box 12194, Research Triangle Park, NC 27709
    • ,
  • John S. Wittenborn, BS

      Affiliations

    • RTI International, Research Triangle Park, NC
    • ,
  • Joel E. Segel, BA

      Affiliations

    • RTI International, Research Triangle Park, NC
    • ,
  • Nilka R. Burrows, MPH, MT

      Affiliations

    • Centers for Disease Control and Prevention, Atlanta, GA
    • ,
  • Kumiko Imai, PhD

      Affiliations

    • UNICEF Swaziland, Mbabane, Kingdom of Swaziland, Bethesda, MD
    • ,
  • Paul Eggers, PhD

      Affiliations

    • National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
    • ,
  • Meda E. Pavkov, MD, PhD

      Affiliations

    • Centers for Disease Control and Prevention, Atlanta, GA
    • ,
  • Regina Jordan, MPH

      Affiliations

    • Centers for Disease Control and Prevention, Atlanta, GA
    • ,
  • Susan M. Hailpern, DrPH, MS

      Affiliations

    • Centers for Disease Control and Prevention, Atlanta, GA
    • ,
  • Anton C. Schoolwerth, MD, MSHA

      Affiliations

    • Dartmouth Hitchcock Medical Center, Lebanon, NH
    • ,
  • Desmond E. Williams, MD, PhD

      Affiliations

    • Centers for Disease Control and Prevention, Atlanta, GA
    • ,
  • Centers for Disease Control and Prevention CKD Initiative

Received 28 April 2009 ,Accepted 12 November 2009.

References 

  1. Coresh J, Selvin E, Stevens L, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038–2047
  2. Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol. 2004;15:1307–1315
  3. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–1305
  4. Smith DH, Nichols GA, Gullion CM, Johnson ES, Keith D. Predicting costs of care in chronic kidney disease: the role of comorbid conditions. Internet J Nephrol. 2007;4(1):http://www.ispub.com/ostia/index.php?xmlFilePath=journals/ijne/vol4n1/cost.xml. Accessed October 31, 2007
  5. National Kidney Foundation. Guideline 5: assessment of proteinuria (K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: evaluation, classification and stratification). Am J Kidney Dis. 2002;39(suppl 1):93–102http://www.kidney.org/professionals/kdoqi/guidelines_ckd/p5_lab_g5.htm. Accessed March 30, 2006
  6. Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR. Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA. 2003;290(23):3101–3114
  7. Palmer AJ, Valentine WJ, Chen R, et al. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA. Nephrol Dial Transplant. 2008;23:1216–1223
  8. National Kidney Foundation. K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007;49(suppl 2):12–154
  9. Hoerger TJ, Wittenborn JS, Segel JE, et al. A health policy model of CKD (1: Model construction, assumptions, and validation of health consequences). Am J Kidney Dis. 2010;55(3):452–462
  10. US Renal Data System. USRDS 2006 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. In: Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006;p. 53;Fig 1.8. http://www.usrds.org/2006/pdf/01_ckd_06.pdf. Accessed July 30, 2009
  11. Sarafidis PA, Riehle J, Bogojevic Z, et al. A comparative evaluation of various methods for microalbuminuria screening. Am J Nephrol. 2008;28(2):324–329
  12. Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ. 2004;329:828
  13. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285:2719–2728
  14. Ruggenenti P, Perna A, Mosconi L, et al. GISEN Group Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857–1863
  15. Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999;354:359–364
  16. US Renal Data System. USRDS 2006 Annual Data Report: Incidence of Reported ESRD Reference Tables. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006;Table A.2, p 10. http://www.usrds.org/2006/ref/A_incidence_06.pdf. Accessed July 30, 2009
  17. Centers for Medicare & Medicaid Services. Physician fee schedule search, 2007. http://www.cms.hhs.gov/pfslookup/02_PFSsearch.aspAccessed July 20, 2007
  18. Centers for Medicare & Medicaid Services. 2007 Clinical diagnostic laboratory fee schedule—07CLAB. http://www.cms.hhs.gov/ClinicalLabFeeSched/02_clinlab.asp#TopOfPageAccessed July 20, 2007
  19. Boulware LE, Troll MU, Jaar BG, Myers DI, Powe NR. Identification and referral of patients with progressive CKD: a national study. Am J Kidney Dis. 2006;48(2):192–204
  20. Agency for Healthcare Research and Quality (AHRQ). 2005 National estimates on hospital use for all patients. HCUP Nationwide Inpatient Sample (NIS). http://hcupnet.ahrq.gov/Accessed July 20, 2007
  21. Rodby RA, Chiou CF, Borenstein J, et al. The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy. Clin Ther. 2003;25:2103–2119
  22. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860
  23. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised trial. Lancet. 2003;361(9352):117–124
  24. Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data. Ann Intern Med. 2001;135:73–87
  25. Drug Topics Redbook. Oradell, NJ: Medical Economics Co; 2007;
  26. Agency for Healthcare Research and Quality. 2004 State estimates on emergency department use (HCUP State Inpatient Database (SID) and State Emergency Department Databases (SEDD)). http://hcupnet.ahrq.gov/Accessed July 20, 2007
  27. US Renal Data System. USRDS 2006 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. In: Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006;p. 208;Fig 11.3. http://www.usrds.org/2006/pdf/01_ckd_06.pdf. Accessed July 30, 2009
  28. US Renal Data System. USRDS 2006 Annual Data Report: Incidence of Reported ESRD Reference Tables. In: Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006;p. 6;Table A.1. http://www.usrds.org/2006/ref/A_incidence_06.pdf. Accessed July 30, 2009
  29. US Renal Data System. USRDS 2006 Annual Data Report: Prevalence of Reported ESRD Reference Tables. In: Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006;p. 40;Table B.1. http://www.usrds.org/2006/ref/B_prevalence_06.pdf. Accessed July 30, 2009
  30. Gorodetskaya I, Zenios S, McCulloch CE, et al. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int. 2005;68:2801–2808
  31. Tsevat J, Goldman L, Soukup JR, et al. Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Making. 1993;13(2):161–165
  32. Nease RF, Kneeland T, O'Connor GT, et al. Variation in patient utilities for outcomes of the management of chronic stable angina. JAMA. 1995;273(15):1185–1190
  33. Meenan RT, Saha S, Chou R, et al. Cost-effectiveness of echocardiography to identify intracardiac thrombus among patients with first stroke or transient ischemic attack. Med Decis Making. 2007;27:161–177
  34. Gold MR, Siegel JE, Russell LB. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996;
  35. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–254
  36. Rule AD, Lanson TS, Bergstralh EJ, et al. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med. 2004;141:929–937
  37. Snyder JJ, Foley RN, Collins AJ. Prevalence of CKD in the United States: a sensitivity analysis using the National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis. 2009;53(2):218–228
  38. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612
  39. Arias E. United States life tables, 2003. Natl Vital Stat Rep. 2006;54(14):http://www.cdc.gov/nchs/data/nvsr/nvsr54/nvsr54_14.pdf. Accessed July 29, 2009
  40. Grosse SD. Cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoeconomic Outcomes Res. 2008;8(2):165–178
  41. Braithwaite RS, Meltzer DO, King JT, Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?. Med Care. 2008;46:349–356

 Originally published online as doi:10.1053/j.ajkd.2009.11.017 on February 1, 2010.

 Information on members of the Centers for Disease Control and Prevention CKD Initiative is available at www.cdc.gov/diabetes/projects/kidney.htm.

PII: S0272-6386(09)01598-4

doi: 10.1053/j.ajkd.2009.11.017

American Journal of Kidney Diseases
Volume 55, Issue 3 , Pages 463-473 , March 2010

Article Tools

* Image Usage & Resolution